Down-regulation of A20 mRNA expression in peripheral blood mononuclear cells from MDS patients

Figures & data

Figure 1. The relatively expression levels of A20 mRNA in PBMC from MDS patients (n = 27) and healthy controls (n = 27) by Quantitative Real-Time RT-PCR.

Table 1. The levels of plasma cytokines from MDS patients (n = 30) and healthy controls (n = 30) by Luminex Liquid Suspension Chip.

Cytokines (pg/ml)	Healthy Controls Median (Range)	MDS Patients Median (Range)	P value
TNF-α	4.32 (2.73–10.20)	7.71 (3.03–48.26)	<0.001
IFN-γ	7.31 (0.95–16.00)	7.28 (1.94–20.27)	0.811
IL-1β	1.97 (0.61–3.06)	1.65 (0.14–8.96)	0.46
IL-6	0.21 (0.21–12.13)	0.77 (0.09–33.56)	0.97
IL-8	0.42 (0.42–24.28)	6.35 (0.36–100.09)	<0.001
TGF-β1	7948.82 (2620.96–26502.46)	5648.67 (869.26–31788.08)	0.198

Table

Demographic variable	MDS patients	Healthy controls
Sex, n(%)
Male	18(60%)	17(57%)
Female	12(40%)	13(43%)
Age (years)	66(31–81)	57(28-84)
Hemoglobin (g/L)	56(23–150)	–
Platelets counts (10^9/L)	31(1.0–336)	–
Neutrophil counts (10^9/L)	1.1(0.2–6.0)	–
WHO classification, n(%)
MDS-SLD	5(17%)	–
MDS-MLD	9(30%)	–
MDS-RS-SLD	0(0%)	–
MDS-RS-MLD	1(3%)	–
MDS-del (5q)	1(3%)
MDS-EB1	5(17%)
MDS-EB2	9(30%)
Karyotype, n(%)
Normal	26(87%)
Del (5q)	1(3%)
+8	1(3%)
Del(20q)	1(3%)
Complex	1(3%)
BM blast count	3.5%(0.5%–14.6%)	–
IPSS-R	4.5 (2.0–7.0)	–

* Except where indicated otherwise, values are the mean (range).

WHO: World Health Organization; BM: bone marrow; SLD: single lineage dysplasia; MLD: multilineage dysplasia; RS: ring sideroblasts; EB: excess blasts; IPSS-R: Revised International Prognostic Scoring System.